- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00435604
A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase
Phase I Dose-Ranging Randomized Double-Blinded Controlled Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase
This Phase I, randomized, double-blinded, within-subject controlled, two-way crossover study comparing the time to inject (flow rate), safety, and tolerability of a subcutaneously (SC) administered, viscous antibody solution of with and without human recombinant hyaluronidase (rHuPH20) in volunteer subjects.
The study hypothesizes that the time required to complete a 20-mL SC injection of a viscous antibody with rHuPH20 will be comparable or shorter than the time required for the injection without rHuPH20.
Studieöversikt
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 1
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Volunteers of either sex, age 18 to 65 years, inclusive.
- Intact normal skin on both upper extremities without tattoos or potentially obscuring pigmentation or lesions.
- Vital signs (BP, HR, temperature, respiratory rate) within normal range.
- Metabolic panel (e.g., sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, AST, ALT, alkaline phosphatase, total bilirubin, albumin, and total protein) within normal range within 7 days of injection.
- A negative serum or urine pregnancy test (if female of child-bearing potential) within 7 days of injection.
- Female subjects of child-bearing potential must be practicing effective birth control or abstinence currently and plan to continue to do so for the duration of the study.
- Decision-making capacity and willingness and ability to comply with the requirements for full completion of the trial.
- Willingness and ability to sign an informed consent document.
Exclusion Criteria:
- Upper extremity edema.
- Upper extremity pathology that could interfere with any protocol-specified outcome assessment (e.g., cellulitis, lymphatic disorder or prior surgery, preexisting pain syndrome, previous mastectomy and/or axillary lymph node dissection, etc.).
- Contraindication to an antibody, such as known history of anaphylactic or severe systemic reactions.
- Known predisposition to renal insufficiency or renal failure, including diabetes mellitus, volume depletion, sepsis, paraproteinemia, and subjects receiving known nephrotoxic drugs.
- Known allergy to hyaluronidase or any other ingredient in the formulation of Hylenex.
- Known allergy to bee or vespid venom.
- Known coagulopathy.
- Pregnancy or breast-feeding woman.
- Known clinically significant cardiovascular, gastrointestinal, hepatic, neurological, psychiatric, endocrine, cancer, HIV infection, diabetes mellitus, intercurrent illness such as influenza, or other major systemic disease that would unduly risk the subject's safety or interfere with the interpretation of results.
- Participation in a study of any investigational drug or device within 30 days of enrollment in this study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Dubbel
Vad mäter studien?
Primära resultatmått
Resultatmått |
---|
The time to inject 20 mL of a viscous antibody solution with and without rHuPH20.
|
Sekundära resultatmått
Resultatmått |
---|
Assess the time required for a subcutaneous injection with various doses of rHuPH20, safety, tolerability.
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Anoshie Ratnayake, M.D., Principal Investigator
Studieavstämningsdatum
Studera stora datum
Studiestart
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- HZ2-07-01
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Friska
-
University of MiamiJames and Esther King Biomedical Research ProgramAvslutadHealthy Lifetime Icke-rökareFörenta staterna
-
University of LeicesterNational Institute for Health Research, United KingdomAvslutadPatienter med hjärtsvikt och konserverad ejektionsfraktion - HFpEF | Patienter med hjärtsvikt med reducerad ejektionsfraktion - HFrEF | Healthy Controls Group - ålders- och könsmatchad
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesAvslutadParkinsons sjukdom | Healthy Controls Group - ålders- och könsmatchadFrankrike
Kliniska prövningar på Hylenex
-
Halozyme TherapeuticsAvslutad
-
Tissa Hata, MDAvslutad
-
Halozyme TherapeuticsBaxter Healthcare CorporationAvslutad
-
Halozyme TherapeuticsBaxter Healthcare CorporationAvslutad
-
Vanderbilt University Medical CenterBaxter Healthcare CorporationAvslutadUttorkning | Pediatrik | HjärteffektFörenta staterna
-
Baxter Healthcare CorporationHalozyme TherapeuticsAvslutad
-
Johns Hopkins UniversityRekrytering
-
Steve Yoelin M.D. Medical Associates, Inc.Avslutad
-
Stanford UniversityUniversity of Colorado, DenverAvslutad
-
Baxter Healthcare CorporationPPD; Halozyme TherapeuticsAvslutad